LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Your last searches

  1. TI=Efficacy and safety of the pharmacotherapy used in the management of hyperkalemia: a systematic review
  2. AU=Molina J M AU=Molina J M

Search results

Result 1 - 3 of total 3

Search options

  1. Article: Efficacy and safety of the pharmacotherapy used in the management of hyperkalemia: a systematic review.

    Varallo, Fabiana R / Trombotto, Victória / Lucchetta, Rosa C / Mastroianni, Patricia de C

    Pharmacy practice

    2019  Volume 17, Issue 1, Page(s) 1361

    Abstract: ... the purpose to evaluate the efficacy, effectiveness, and safety of hyperkalemia pharmacotherapies.: Methods ... retrospective cohort were identified regarding efficacy and safety of 24 different alternatives. The management ... such as sodium zirconium cyclosilicate and patiromer; however, their safety and efficacy or effectiveness have ...

    Abstract Background: Although the management of hyperkalemia follows expert guidelines, treatment approaches are based on traditionally accepted practice standards. New drugs have been assessed such as sodium zirconium cyclosilicate and patiromer; however, their safety and efficacy or effectiveness have not yet been compared to traditional pharmacotherapy.
    Objective: The present systematic review had the purpose to evaluate the efficacy, effectiveness, and safety of hyperkalemia pharmacotherapies.
    Methods: PubMed, LILACS, Cochrane Library, and ClinicalTrials were searched through November 2018. Clinical trial, cohort and case-control were searched. The risk of bias (RoB v2.0 and ROBINS-I) and quality of evidence (GRADE) at the level of outcomes were assessed.
    Results: Sixteen clinical trials and one retrospective cohort were identified regarding efficacy and safety of 24 different alternatives. The management of hyperkalemia remains empirical and off-label, since sodium zirconium cyclosilicate and patiromer are not available in several countries and further studies are required to assess efficacy, effectiveness and safety. Sodium or calcium polystyrene sulfonate (moderate confidence), sodium zirconium cyclosilicate (moderate confidence), and insulin plus dextrose (moderate confidence) showed superior efficacy to, respectively, placebo, no treatment, placebo, and dextrose. Other therapies (low confidence) showed similar efficacy compared to active or inactive alternatives. Most of the adverse events reported were nonspecific, so it was not possible to assign the cause and to classify as defined or probable.
    Conclusions: Comparative cohort and case-control studies are need to evaluate the safety and effectiveness of new and traditional pharmacotherapies to support the development of guidelines about acute and chronic hyperkalemia, with high-quality evidence.
    Language English
    Publishing date 2019-03-04
    Publishing country Spain
    Document type Journal Article
    ZDB-ID 2414565-8
    ISSN 1886-3655 ; 1885-642X
    ISSN (online) 1886-3655
    ISSN 1885-642X
    DOI 10.18549/PharmPract.2019.1.1361
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Safety and efficacy of new potassium binders on hyperkalemia management in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials.

    Carvalho, Pedro E P / Veiga, Thiago M A / Lacerda, Henrique / Tofanelli, Matheus R / Gewehr, Douglas M / Nunes, Maria C P / Simões E Silva, Ana C

    Clinical research in cardiology : official journal of the German Cardiac Society

    2023  Volume 112, Issue 7, Page(s) 991–1002

    Abstract: Background: Hyperkalemia leads to suboptimal use of evidence-based therapies in patients ... The use of new potassium binders Patiromer or SZC in patients with HF at risk for hyperkalemia increased ... with heart failure (HF). Therefore, we aimed to assess whether new potassium binders are effective and safe ...

    Abstract Background: Hyperkalemia leads to suboptimal use of evidence-based therapies in patients with heart failure (HF). Therefore, we aimed to assess whether new potassium binders are effective and safe to promote medical optimization in patients with HF.
    Methods: MEDLINE, Cochrane, and Embase were searched for randomized controlled trials (RCTs) that reported outcomes after initiation of Patiromer or Sodium Zirconium Cyclosilicate (SZC) versus placebo in patients with HF at high risk of hyperkalemia development. Risk ratios (RR) with 95% confidence intervals (CI) were pooled with a random effects model. Quality assessment and risk of bias were performed according to Cochrane recommendations.
    Results: A total of 1432 patients from 6 RCTs were included, of whom 737 (51.5%) patients received potassium binders. In patients with HF, potassium binders increased the use of renin-angiotensin-aldosterone inhibitors (RR 1.14; 95% CI 1.02-1.28; p = 0.021; I
    Conclusion: The use of new potassium binders Patiromer or SZC in patients with HF at risk for hyperkalemia increased the rates of medical therapy optimization with renin-angiotensin-aldosterone inhibitors and reduced the incidence of hyperkalemia, at the cost of an increased prevalence of hypokalemia.
    MeSH term(s) Humans ; Hyperkalemia/drug therapy ; Hyperkalemia/etiology ; Potassium ; Hypokalemia/complications ; Renin/pharmacology ; Renin/therapeutic use ; Aldosterone/pharmacology ; Aldosterone/therapeutic use ; Randomized Controlled Trials as Topic ; Heart Failure/complications ; Heart Failure/drug therapy ; Renin-Angiotensin System ; Mineralocorticoid Receptor Antagonists/therapeutic use ; Angiotensins/pharmacology ; Angiotensins/therapeutic use
    Chemical Substances Potassium (RWP5GA015D) ; Renin (EC 3.4.23.15) ; Aldosterone (4964P6T9RB) ; Mineralocorticoid Receptor Antagonists ; sodium zirconium cyclosilicate (D652ZWF066) ; Angiotensins
    Language English
    Publishing date 2023-05-04
    Publishing country Germany
    Document type Meta-Analysis ; Systematic Review ; Journal Article
    ZDB-ID 2213295-8
    ISSN 1861-0692 ; 1861-0684
    ISSN (online) 1861-0692
    ISSN 1861-0684
    DOI 10.1007/s00392-023-02215-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Efficacy and safety of eplerenone in the management of mild to moderate arterial hypertension: systematic review and meta-analysis.

    Pelliccia, Francesco / Patti, Giuseppe / Rosano, Giuseppe / Greco, Cesare / Gaudio, Carlo

    International journal of cardiology

    2014  Volume 177, Issue 1, Page(s) 219–228

    Abstract: ... CI 1.1 to 1.71; p = 0.005), whereas the occurrence of serious adverse events and hyperkalemia was ... that eplerenone has a reassuring safety profile and is effective in lowering blood pressure in patients with mild ... studies. To systematically assess the efficacy and tolerability of eplerenone in patients with mild ...

    Abstract Background: The role of eplerenone in arterial hypertension has been investigated only in small studies. To systematically assess the efficacy and tolerability of eplerenone in patients with mild to moderate arterial hypertension, we did a meta-analysis of controlled randomized trials.
    Methods: We performed an electronic literature search of Medline, Pubmed, Scopus and Cochrane databases for studies published up to March 31, 2014. Randomized studies comparing eplerenone with placebo or other antihypertensive drugs for net reduction of systolic and diastolic blood pressures (SBP; DBP) from baseline and for incidence of adverse events were considered. Weighted mean differences (WMD) and odds ratios with 95% confidence interval were calculated for continuous and dichotomous data, respectively.
    Results: A total of 11 trials and 3566 patients were overall included. Compared to placebo, eplerenone significantly reduced either SBP [WMD -8.07, 95% CI -8.17 to -7.96 mm Hg, p < 0.00001] and DBP [WMD -4.08, -4.15 to -4.01 mm Hg, p < 0.00001]. In the overall comparison, reduction of both SBP and DBP with eplerenone was greater than other antihypertensive agents (WMD for SBP -1.50 mm Hg, p < 0.0001; WMD for DBP -0.54 mm Hg, p < 0.00001); this was essentially driven by a greater anti-hypertensive action vs enalapril and losartan for SBP and vs losartan for DBP. Rates of any adverse event were significantly higher with eplerenone than placebo (odds ratio 1.37, 95% CI 1.1 to 1.71; p = 0.005), whereas the occurrence of serious adverse events and hyperkalemia was similar. There was no difference between eplerenone and other antihypertensives in the frequency of any or serious adverse events, whereas hyperkalemia was more common with eplerenone (odds ratio 2.36, 95% CI 1.00 to 5.57; p = 0.05).
    Conclusion: This study-level meta-analysis provides a robust evidence that eplerenone has a reassuring safety profile and is effective in lowering blood pressure in patients with mild-to-moderate hypertension; this effect is at least comparable to that of other anti-hypertensive agents (PROSPERO Registration No. CRD42014010071).
    MeSH term(s) Blood Pressure/drug effects ; Humans ; Hypertension/drug therapy ; Hypertension/physiopathology ; Mineralocorticoid Receptor Antagonists/therapeutic use ; Severity of Illness Index ; Spironolactone/analogs & derivatives ; Spironolactone/therapeutic use ; Treatment Outcome
    Chemical Substances Mineralocorticoid Receptor Antagonists ; Spironolactone (27O7W4T232) ; eplerenone (6995V82D0B)
    Language English
    Publishing date 2014-11-15
    Publishing country Netherlands
    Document type Journal Article ; Meta-Analysis ; Review
    ZDB-ID 779519-1
    ISSN 1874-1754 ; 0167-5273
    ISSN (online) 1874-1754
    ISSN 0167-5273
    DOI 10.1016/j.ijcard.2014.09.091
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top